Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis

[1]  G. Salum,et al.  ADHD prevalence estimates across three decades: an updated systematic review and meta-regression analysis. , 2013, International journal of epidemiology.

[2]  T. Banaschewski,et al.  European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit/hyperactivity disorder , 2013, European Neuropsychopharmacology.

[3]  R. Cunill,et al.  Atomoxetine for attention deficit hyperactivity disorder in the adulthood: a meta‐analysis and meta‐regression , 2013, Pharmacoepidemiology and drug safety.

[4]  D. Coghill,et al.  Efficacy and Safety of Lisdexamfetamine Dimesylate and Atomoxetine in the Treatment of Attention-Deficit/Hyperactivity Disorder: a Head-to-Head, Randomized, Double-Blind, Phase IIIb Study , 2013, CNS Drugs.

[5]  Janet B W Williams,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[6]  J. Ramos-Quiroga,et al.  Efficacy and safety of prolonged-release OROS methylphenidate in adults with attention deficit/hyperactivity disorder: A 13-week, randomized, double-blind, placebo-controlled, fixed-dose study , 2013, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[7]  J. McGough,et al.  Atomoxetine Treatment of Attention-Deficit/Hyperactivity Disorder in Young Adults With Assessment of Functional Outcomes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial , 2013, Journal of clinical psychopharmacology.

[8]  T. Banaschewski,et al.  Does Atomoxetine Improve Executive Function, Inhibitory Control, and Hyperactivity?: Results From a Placebo-Controlled Trial Using Quantitative Measurement Technology , 2012, Journal of clinical psychopharmacology.

[9]  R. Weisler,et al.  Randomized Clinical Study of a Histamine H3 Receptor Antagonist for the Treatment of Adults with Attention-Deficit Hyperactivity Disorder , 2012, CNS Drugs.

[10]  M. Brod,et al.  Comparison of the burden of illness for adults with ADHD across seven countries: a qualitative study , 2012, Health and Quality of Life Outcomes.

[11]  L. Adler,et al.  An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD. , 2012, The Journal of clinical psychiatry.

[12]  R. Dittmann,et al.  A Randomized, Waiting List-Controlled 12-Week Trial of Atomoxetine in Adults with ADHD , 2011, Pharmacopsychiatry.

[13]  E. Walker,et al.  Diagnostic and Statistical Manual of Mental Disorders , 2013 .

[14]  R. Findling,et al.  Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. , 2011, Journal of the American Academy of Child and Adolescent Psychiatry.

[15]  T. Wigal,et al.  Effect Size of Lisdexamfetamine Dimesylate in Adults with Attention-Deficit/Hyperactivity Disorder , 2011, Postgraduate medicine.

[16]  L. Wietecha,et al.  Once-Daily Treatment With Atomoxetine in Adults With Attention-Deficit/Hyperactivity Disorder: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial , 2011, Clinical neuropharmacology.

[17]  Sharon B Wigal,et al.  Efficacy and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: sex and age effects and effect size across the day , 2010, Child and adolescent psychiatry and mental health.

[18]  J. Biederman,et al.  A Randomized, 3-Phase, 34-Week, Double-Blind, Long-Term Efficacy Study of Osmotic-Release Oral System-Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder , 2010, Journal of clinical psychopharmacology.

[19]  Michele Tarsilla.  Cochrane Handbook for Systematic Reviews of Interventions , 2010, Journal of MultiDisciplinary Evaluation.

[20]  J. Buitelaar,et al.  Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis , 2010, European Child & Adolescent Psychiatry.

[21]  J. Alda,et al.  Evaluation of atomoxetine for first-line treatment of newly diagnosed, treatment-naïve children and adolescents with attention deficit/hyperactivity disorder , 2009, Current medical research and opinion.

[22]  K. Schuh,et al.  Once-Daily Atomoxetine for Treating Pediatric Attention-Deficit/Hyperactivity Disorder: Comparison of Morning and Evening Dosing , 2009, Clinical pediatrics.

[23]  T. Spencer,et al.  Efficacy and Safety of OROS Methylphenidate in Adults With Attention-Deficit/Hyperactivity Disorder: A Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Dose-Escalation Study , 2009, Journal of clinical psychopharmacology.

[24]  T. Spencer,et al.  Once-Daily Atomoxetine for Adult Attention-Deficit/Hyperactivity Disorder: A 6-Month, Double-Blind Trial , 2009, Journal of clinical psychopharmacology.

[25]  J. Biederman,et al.  Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. , 2008, The Journal of clinical psychiatry.

[26]  Rodney J. Moore,et al.  Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. , 2008, The American journal of psychiatry.

[27]  J. Buitelaar,et al.  A Randomized, Placebo-Controlled Trial of Three Fixed Dosages of Prolonged-Release OROS Methylphenidate in Adults with Attention-Deficit/Hyperactivity Disorder , 2008, Biological Psychiatry.

[28]  B. Horta,et al.  The worldwide prevalence of ADHD: a systematic review and metaregression analysis. , 2007, The American journal of psychiatry.

[29]  J. McGough,et al.  Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. , 2007, Clinical therapeutics.

[30]  S. Faraone,et al.  Comparing the efficacy of medications for ADHD using meta-analysis. , 2006, MedGenMed : Medscape general medicine.

[31]  K. Schuh,et al.  Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial. , 2004, Pediatrics.

[32]  S. West,et al.  Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies , 2003, Biological Psychiatry.

[33]  J. Biederman,et al.  Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder. , 2002, The Journal of clinical psychiatry.

[34]  S. West,et al.  Once-Daily Atomoxetine Treatment for Children and Adolescents With Attention Deficit Hyperactivity Disorder: A Randomized, Placebo-Controlled Study , 2002 .

[35]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.

[36]  J. Wernicke,et al.  Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. , 2001, Pediatrics.

[37]  P. Lachenbruch.  Statistical Power Analysis for the Behavioral Sciences (2nd ed.) , 1989 .

[38]  W. G. Cochran.  The combination of estimates from different experiments. , 1954 .

[39]  T. Wilens,et al.  Safety and efficacy of ABT-089 in pediatric attention-deficit/hyperactivity disorder: results from two randomized placebo-controlled clinical trials. , 2011, Journal of the American Academy of Child and Adolescent Psychiatry.

[40]  J. Higgins.  Cochrane handbook for systematic reviews of interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration , 2011 .

[41]  F. Sallee,et al.  A randomized, double-blind, placebo-controlled, parallel-group study of methylphenidate transdermal system in pediatric patients with attention-deficit/hyperactivity disorder. , 2008, The Journal of clinical psychiatry.

[42]  J. McGough,et al.  Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder. , 2006, Archives of pediatrics & adolescent medicine.